Dataset from Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

This is an open-label, single-arm, multicenter, Phase IIIb study to evaluate the safety and
tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in female patients
with HER2-positive metastatic or locally recurrent breast cancer. Enrolled patients are to
receive study medication until disease progression, unacceptable toxicity, withdrawal of
consent, death, or predefined study end, whichever occurs first. The anticipated time on
study treatment is approximately 24 months. The target sample size is 400.